Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-κB

Journal of Pharmacological Sciences

Volumn 111, Issue 2, 2009, Pages 124-136

  So, Yong Lee ^a   Jin, Suk Cho ^a   Dong, Yeon Yuk ^a   Dong, Cheul Moon ^a   Jae, Kyung Jung ^a   Hwan, Soo Yoo ^a   Young, Moon Lee ^a   Sang, Bae Han ^a   Oh, Ki Wan ^a   Jin, Tae Hong ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Apoptotic cell death; Combination treatment; Docetaxel; Nuclear transcription factor B (NF B); Obovatol

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAGNOLIA EXTRACT; OBOVATOL; PACLITAXEL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; PLANT LEAF; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 70350475246     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09048FP     Document Type: Article

References (61)

1. Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 2002;16:1053-1068. (Pubitemid 34618844)
2. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285-296. (Pubitemid 39061110)
3. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-466. (Pubitemid 39329586)
4. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon? J Cell Biochem. 2004;91:100-117.
5. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of Ikappa B alpha and NF-kappB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999;18:7389-7394.
6. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B related proteins in tumor cell lines. Biochem Pharmacol. 1994;47:145-149. (Pubitemid 24045827)
7. Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery. 2001;130:363-369. (Pubitemid 32721692)
8. Cusack JC Jr, Liu R, Baldwin AS Jr. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res. 2000;60:2323-2330.
9. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res. 2000;60:4426-4432. (Pubitemid 32103621)
10. Dong QG, Sclabas GM, Fujioka S. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene. 2002;21:6510-6519. (Pubitemid 35155455)
11. Oyaizu H, Adachi Y, Okumura T. Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol Rep. 2001;8:825-829. (Pubitemid 33758131)
12. Son DJ, Park MH, Chae SJ, Moon SO, Lee JW, Song HS, et al. Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor kappaB. Mol Cancer Ther. 2007;6:675-683.
13. Zhang H, Morisaki T, Nakahara C. PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene. 2003;22:2088-2096. (Pubitemid 36539559)
14. Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS. NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery. 2001;130:143-150. (Pubitemid 32721661)
15. Lee SH, Lee CW, Lee JW, Choi MS, Son DJ, Chung YB, et al. Induction of apoptotic cell death by 2′-hydroxycinnamaldehyde is involved with ERK-dependent inactivation of NF-kappaB in TNF-alpha-treated SW620 colon cancer cells. Biochem Pharmacol. 2005;70:1147-1157.
16. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist. 2004;9:282-294. (Pubitemid 38765090)
17. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643-2655.
18. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004;22:1071-1077. (Pubitemid 41095040)
19. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-2362. (Pubitemid 30415821)
20. Okada S, Sakata Y, Matsuno S, Kurihara M, Sasaki Y, Ohashi Y, et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer. 1999;80:438-443.
21. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002; 94:97-103. (Pubitemid 34049046)
22. Ferraresi V, Milella M, Vaccaro A, D'Ottavio AM, Papaldo P, Nisticò C, et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol. 2000;23:132-139.
23. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res. 2004; 10:7645-7654. (Pubitemid 39557528)
24. Chan SS, Zhao M, Lao L, Fong HH, Che CT. Magnolol and honokiol account for the anti-spasmodic effect of Magnolia officinalis in isolated guinea pig ileum. Planta Med. 2008;74: 381-384. (Pubitemid 351578793)
25. Han SJ, Bae EA, Trinh HT, Yang JH, Youn UJ, Bae KH, et al. Magnolol and honokiol: inhibitors against mouse passive cutaneous anaphylaxis reaction and scratching behaviors. Biol Pharm Bull. 2007;30:2201-2203. (Pubitemid 350097051)
26. Park J, Lee J, Jung E, Park Y, Kim K, Park B, et al. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol. 2004; 496:189-195.
27. Nagase H, Ikeda K, Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Med. 2001;67:705-708.
28. Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, et al. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer. 2007;109:1279-1289. (Pubitemid 46466554)
29. Choi MS, Lee SH, Cho HS, Kim Y, Yun YP, Jung HY, et al. Inhibitory effect of obovatol on nitric oxide production and activation of NF-kappaB/MAP kinases in lipopolysaccharide-treated RAW 264.7cells. Eur J Pharmacol. 2007;556:181-189. (Pubitemid 46098933)
30. Lee SY, Yuk DY, Song HS, Yoon do Y, Jung JK, Moon DC, et al. Growth inhibitory effects of obovatol through induction of apoptotic cell deathin prostate and colon cancer by blocking of NF-kappaB. Eur J Pharmacol. 2007;582:17-25.
31. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-681.
32. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006;66:3347-3350.
33. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005;65:6934-6942. (Pubitemid 41060733)
34. Banerjee S, Zhang Y, Ali S. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005;65:9064-9072. (Pubitemid 41377399)
35. Li Y, Ellis KL, Ali S. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004;28:90-95.
36. Hwang JT, Ha J, Park OJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2signaling pathways. Biochem Biophys Res Commun. 2005;332:433-440. (Pubitemid 40731495)
37. Lev-Ari S, Strier L, Kazanov D. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res. 2005;11:6738-6744. (Pubitemid 41339017)
38. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activation levels and in IAP gene expression. Cancer Lett. 2005;224:53-65.
39. Chuang SE, Yeh PY, Lu YS. Basal levels and patterns of anti-cancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol. 2002;63: 1709-1716.
40. Barkett M, Gilmore TD. Control of apoptosis by Rel /NF-κB transcription factors. Oncogene. 1999;18:6910-6924.
41. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
42. Perkins ND. The Rel /NF-κB family: friend and foe. Trends Biochem Sci. 2000;25:434-440.
43. Marianneau P, Cardona A, Edelman L, Deubel V, Despres P. Dengue virus replication in human hepatoma cells activates NF-κB which in turn induces apoptotic cell death. J Virol. 2007;71:3244-3249.
44. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol Cell. 1998;1:543-551. (Pubitemid 128374690)
45. Qin ZH, Wang Y, Nakai M, Chase TN. Nuclear factor-κB contributes to excitotoxin-induced apoptosis in rat striatum. Mol Pharmacol. 1998;53:33-42. (Pubitemid 28068370)
46. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-κB is activated and promotes cell death in focal cerebral ischemia. Nat Med. 1999;5:554-559. (Pubitemid 29220215)
47. Amer AB, Baltimore D. An essential role for NF-κB in preventing TNF-α induced cell death. Science. 1996;274:782-784. (Pubitemid 26398258)
48. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 1996;274:787-789.
49. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274:784-787.
50. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969. (Pubitemid 28022832)
51. Waddick KG, Uckun FM. Innovative treatment programs against cancer: II. Nuclear factor-κB (NF-κB) as a molecular target. Biochem Pharmacol. 1999;57:9-17.
52. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med. 1999;5: 412-417. (Pubitemid 29180579)
53. Lin ZP, Boller YC, Amer SM, Russell RL, Pacelli KA, Patierno SR, et al. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-κB activation in drug resistance. Cancer Res. 1998;58:3059-3065.
54. Millikan R, Baez L, Banerjee T, Wade J, Edwards K, Winn R, et al. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol. 2001;6:111-115. (Pubitemid 32416464)
55. Lee HR, Cheong HJ, Kim SJ, Lee NS, Park HS, Won JH. Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells. Oncol Rep. 2008;20:41-47.
56. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. Honokiol potentiates apoptosis, suppresses osteoclasto-genesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res. 2006;4: 621-633. (Pubitemid 44497215)
57. Jiang QQ, Fan LY, Yang GL, Guo WH, Hou WL, Chen LJ, et al. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer. 2008;8:242.
58. Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, et al. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol. 2008;591:43-51.
59. Hou W, Chen L, Yang G, Zhou H, Jiang Q, Zhong Z, et al. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models. Phytother Res. 2008; 22:1125-1132.
60. Luo H, Zhong Q, Chen LJ, Qi XR, Fu AF, Yang HS, et al. Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer. J Cancer Res Clin Oncol. 2008;134:937-945.
61. Ban JO, Yuk DY, Woo KS, Kim TM, Lee US, Jeong HS, et al. Inhibition of cell growth and induction of apoptosis via inactivation of NF-kappaB by a sulfurcompound isolated from garlic in human colon cancer cells. J Pharmacol Sci. 2007;104:374-383.